Prosemble is excited to announce that we’ve received funding through the Innovate UK Growth Catalyst Early Stage: New Innovators competition. This award will support the further development of our Full-Stack AI Platform, designed to predict drug efficacy, toxicity, and cost-effectiveness. Our platform incorporates innovative technologies, including CombChem for compound generation, ShackEr for high-throughput screening, and Galaxy, our novel off-target prediction engine. With a predictive accuracy of 93.3%, our AI models are transforming the drug discovery process, from early-stage development to risk assessment, enhancing both biological and financial outcomes. This funding is a pivotal step in our mission to accelerate the development of safer, more effective therapies.